Want to see FR:BLC full AI Analyst Report?
Bastide le Confort Medical (BLC) AI Stock Analysis
Bastide le Confort Medical
(Paris:BLC)
Strong valuation from low P/E is the primary positive factor, supported by solid cash generation and profitability improvements, though high leverage and weak technical signals limit the overall score.
Bastide le Confort Medical (BLC) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 131.41M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,366
- Price to Earnings (P/E)
- 2.3
- Beta (1Y)
- 0.56
- Revenue Growth
- -1.79%
- EPS Growth
- 10979.07%
- Country
- France
- Employees
- 3,641
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
Bastide le Confort Medical Business Overview & Revenue Model
Company Description
Bastide Le Confort Médical SA specializes in the provision, through both sales and rentals, of medical equipment across France. The company offers a comprehensive array of items, encompassing comfort and wellness products such as specialized seating...
Bastide le Confort Medical Financial Statement Overview
Summary
Revenue stable with recent net income surge to 58 million and 12% margins boosting profitability; cash flows consistent and positive; however, elevated debt-to-equity at 2.28 remains a key risk.
Income Statement
68PositiveBalance Sheet
42NeutralCash Flow
65Positive| Breakdown | TTM | Jun 2026 | Sep 2025 | Sep 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 482.39M | 482.39M | 491.18M | 529.75M | 508.03M | 468.30M |
| Gross Profit | 50.87M | 50.87M | 333.00M | 354.44M | 333.73M | 306.80M |
| EBITDA | 104.85M | 104.85M | 102.03M | 107.20M | 98.15M | 89.83M |
| Net Income | 58.10M | 58.10M | 528.00K | -900.00K | 12.05M | 13.68M |
Balance Sheet | ||||||
| Total Assets | 575.80M | 575.80M | 661.03M | 647.07M | 657.08M | 632.55M |
| Cash, Cash Equivalents and Short-Term Investments | 48.21M | 48.21M | 25.49M | 23.62M | 36.71M | 22.13M |
| Total Debt | 299.13M | 299.13M | 411.16M | 408.65M | 427.39M | 419.23M |
| Total Liabilities | 444.98M | 444.98M | 589.73M | 566.34M | 568.99M | 545.89M |
| Stockholders Equity | 131.07M | 131.07M | 72.13M | 79.77M | 87.65M | 84.56M |
Cash Flow | ||||||
| Free Cash Flow | 30.77M | 30.77M | 41.74M | 10.64M | 36.65M | -6.51M |
| Operating Cash Flow | 81.78M | 81.78M | 101.82M | 66.04M | 90.28M | 46.76M |
| Investing Cash Flow | 60.08M | 60.08M | -56.44M | -43.65M | -76.27M | -104.74M |
| Financing Cash Flow | -118.31M | -118.31M | -4.33M | -35.55M | -7.89M | 29.43M |
Bastide le Confort Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BLC, the sentiment is Negative. The current price of 18.24 is below the 20-day moving average (MA) of 18.34, below the 50-day MA of 20.10, and below the 200-day MA of 23.21, indicating a bearish trend. The MACD of -0.51 indicates Negative momentum. The RSI at 44.61 is Neutral, neither overbought nor oversold. The STOCH value of 38.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BLC.
Bastide le Confort Medical Peers Comparison
Overall Rating
FR:AI73Outperform
FR:BIM72Outperform
FR:BOI65Neutral
FR:ALCGM60Neutral- FR:BLC60Neutral
FR:VTR39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:AI | 73Outperform | EUR 115.95B | 31.26 | 13.42% | 1.67% | -1.30% | 3.05% |
| FR:BIM | 72Outperform | EUR 10.67B | 24.11 | 11.01% | 1.03% | -3.18% | 22.52% |
| FR:BOI | 65Neutral | EUR 332.85M | 12.62 | 6.82% | 7.18% | -1.80% | 35.22% |
| FR:ALCGM | 60Neutral | EUR 132.62M | -9.00 | -5.44% | ― | -0.98% | ― |
| FR:BLC | 60Neutral | EUR 132.36M | 2.31 | 49.70% | ― | -1.79% | 10979.07% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| FR:VTR | 39Underperform | EUR 49.48M | -1.26 | -15.20% | ― | 8.96% | 41.13% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:BLC | Bastide le Confort Medical | 18.24 | -6.36 | -25.85% | |
| FR:AI | Air Liquide (UK) | 182.56 | 32.24 | 21.45% | |
| FR:BIM | bioMerieux SA | 94.75 | -12.18 | -11.39% | |
| FR:BOI | Boiron SA | 18.80 | -7.79 | -29.29% | |
| FR:ALCGM | Cegedim SA | 9.63 | -1.87 | -16.26% | |
| FR:VTR | Vitura SA | 2.64 | -2.04 | -43.59% |
Bastide le Confort Medical Corporate Events
Bastide boosts profits, cash flow and cuts debt as home healthcare growth accelerates
Groupe Bastide reported 2025-2026 revenue of €482.4m, up 7.7% with organic growth of 7.9%, driven by strong momentum in higher-technology home healthcare services and solid expansion in its Home Care activity. Respiratory and diabetes segments...
Bastide le Confort Medical Updates Share Capital and Voting Rights Structure
Bastide le Confort Medical has disclosed its share capital structure as of 30 September 2026, reporting a total of 7,468,749 shares, comprising 7,365,078 ordinary shares and 103,671 preference shares. The company also reported 11,631,246 theoretical...
Bastide le Confort Medical Updates Share Capital and Voting Rights Structure
Bastide le Confort Medical is a French listed company specializing in medical equipment and home healthcare services, operating in the broader health and medical supplies sector. The group focuses on serving patients and care providers through a port...
Bastide lifts revenue and margins as it outperforms targets and cuts debt
Groupe Bastide reported 2025-2026 annual revenue from continuing operations of €482.9 million, up 7.6% year on year on a restated basis, with organic growth of 7.8% and strong contributions from respiratory and diabetes activities. Including th...
Bastide le Confort Medical Updates Share Capital and Voting Rights Structure
Bastide le Confort Medical has reported its capital structure and voting rights as of 31 July 2026, disclosing a total of 7,468,749 shares, comprising 7,365,078 ordinary shares and 103,671 preference shares. The company also announced 11,631,516 theo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026